Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/52102
Full metadata record
DC FieldValueLanguage
dc.contributor.authorStephen Wrighten_US
dc.contributor.authorMark A. Boyden_US
dc.contributor.authorEvy Yunihastutien_US
dc.contributor.authorMatthew Lawen_US
dc.contributor.authorThira Sirisanthanaen_US
dc.contributor.authorJennifer Hoyen_US
dc.contributor.authorSanjay Pujarien_US
dc.contributor.authorMan Po Leeen_US
dc.contributor.authorKathy Petoumenosen_US
dc.date.accessioned2018-09-04T09:20:58Z-
dc.date.available2018-09-04T09:20:58Z-
dc.date.issued2013-06-28en_US
dc.identifier.issn19326203en_US
dc.identifier.other2-s2.0-84879531443en_US
dc.identifier.other10.1371/journal.pone.0064902en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84879531443&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/52102-
dc.description.abstractBackground: In the Asia-Pacific region many countries have adopted the WHO's public health approach to HIV care and treatment. We performed exploratory analyses of the factors associated with first major modification to first-line combination antiretroviral therapy (ART) in resource-rich and resource-limited countries in the region. Methods: We selected treatment naive HIV-positive adults from the Australian HIV Observational Database (AHOD) and the TREAT Asia HIV Observational Database (TAHOD). We dichotomised each country's per capita income into high/upper-middle (T-H) and lower-middle/low (T-L). Survival methods stratified by income were used to explore time to first major modification of first-line ART and associated factors. We defined a treatment modification as either initiation of a new class of antiretroviral (ARV) or a substitution of two or more ARV agents from within the same ARV class. Results: A total of 4250 patients had 961 major modifications to first-line ART in the first five years of therapy. The cumulative incidence (95% CI) of treatment modification was 0.48 (0.44-0.52), 0.33 (0.30-0.36) and 0.21 (0.18-0.23) for AHOD, T-H and T-L respectively. We found no strong associations between typical patient characteristic factors and rates of treatment modification. In AHOD, relative to sites that monitor twice-yearly (both CD4 and HIV RNA-VL), quarterly monitoring corresponded with a doubling of the rate of treatment modifications. In T-H, relative to sites that monitor once-yearly (both CD4 and HIV RNA-VL), monitoring twice-yearly corresponded to a 1.8 factor increase in treatment modifications. In T-L, no sites on average monitored both CD4 & HIV RNA-VL concurrently once-yearly. We found no differences in rates of modifications for once- or twice-yearly CD4 count monitoring. Conclusions: Low-income countries tended to have lower rates of major modifications made to first-line ART compared to higher-income countries. In higher-income countries, an increased rate of RNA-VL monitoring was associated with increased modifications to first-line ART. © 2013 Wright et al.en_US
dc.subjectAgricultural and Biological Sciencesen_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.titleRates and Factors Associated with Major Modifications to First-Line Combination Antiretroviral Therapy: Results from the Asia-Pacific Regionen_US
dc.typeJournalen_US
article.title.sourcetitlePLoS ONEen_US
article.volume8en_US
article.stream.affiliationsThe Kirby Instituteen_US
article.stream.affiliationsSt. Vincent's Hospital Sydneyen_US
article.stream.affiliationsUniversity of Indonesia, RSUPN Dr. Cipto Mangunkusumoen_US
article.stream.affiliationsChiang Mai Universityen_US
article.stream.affiliationsAlfred Hospitalen_US
article.stream.affiliationsMonash Universityen_US
article.stream.affiliationsInstitute of Infectious Diseasesen_US
article.stream.affiliationsQueen Elizabeth Hospital Hong Kongen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.